Deferred Tax Assets, Valuation Allowance of CRESCENT BIOPHARMA, INC. from 31 Dec 2013 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
CRESCENT BIOPHARMA, INC. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2013 to 31 Dec 2025.
  • CRESCENT BIOPHARMA, INC. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $47,991,000, a 1118% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

CRESCENT BIOPHARMA, INC. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $47,991,000 +$44,051,000 +1118% 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q4 2024 $3,940,000 -$157,411,398 -98% 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q4 2023 $161,351,398 +$11,378,884 +7.6% 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q4 2022 $149,972,514 +$13,358,685 +9.8% 31 Dec 2022 10-K 27 Mar 2024 2023 FY
Q4 2021 $136,613,829 +$21,597,506 +19% 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q4 2020 $115,016,323 +$19,166,292 +20% 31 Dec 2020 10-K 03 Mar 2022 2021 FY
Q4 2019 $95,850,031 +$20,977,404 +28% 31 Dec 2019 10-K 02 Mar 2021 2020 FY
Q4 2018 $74,872,627 +$18,517,834 +33% 31 Dec 2018 10-K 28 Feb 2020 2019 FY
Q4 2017 $56,354,793 +$1,687,556 +3.1% 31 Dec 2017 10-K 06 Mar 2019 2018 FY
Q4 2016 $54,667,237 +$15,230,449 +39% 31 Dec 2016 10-K 06 Mar 2018 2017 FY
Q4 2015 $39,436,788 +$6,781,578 +21% 31 Dec 2015 10-K 01 Mar 2017 2016 FY
Q4 2014 $32,655,210 +$6,202,087 +23% 31 Dec 2014 10-K 29 Feb 2016 2015 FY
Q4 2013 $26,453,123 31 Dec 2013 10-K 16 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.